Domestic pharmaceutical firms lined up to enter generic amlodipine market

Published: 2004-06-11 07:00:00

Updated: 2004-06-11 07:00:00

The Korean government policy to offer preferential treatment for generic and bioequivalence-tested drugs has prompted a number of domestic pharmaceutical firms to flock to the domestic generic amlodipine market, where Pfizer Korea's Norvasc (amlodipine besylate) has held on to its market dominanc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK